Mammary Carcinogenesis: Growth Hormone and IGF-I

Summary

Principal Investigator: D L Kleinberg
Abstract: By systematically delineating the intricate hormonal processes involved in normal mammary gland development and relating them to breast cancer, our mission is to identify potential medical therapies for breast cancer based on these findings. We have proven that GH, through IGF-I, plays a pivotal role in mammary development during puberty and likely during pregnancy. By direct interaction with mammary fat pads, GH induces IGF-I mRNA. Through a potent permissive and synergistic interaction with E2, IGF-I stimulates TEB formation and mammary ductal morphogenesis, and later permits Pg and E2 to interact with it to form alveoli. We now have strong preliminary evidence that IGF-I may act by stimulating the formation of what we have called a "mammary development unit (MDU)", consisting of a TEB in and around which MMP-9 is produced, along with new vessel formation, and an accumulation of mast cells that produce VEGF. MMP-9 may act to enhance the effect of IGF-I on ductal morphogenesis, and angiogenesis. Since IGF-I is known to induce growth of breast cancers, and inhibition of IGF-I can inhibit cancer development and normal development, we speculate that IGF- I represents a common thread linking normal and breast cancer development through similar mechanisms. Our future research will focus on evaluating the role of GH-induced IGF-I and its mechanism of action in mammary development, and cancer development. We propose to study the effects of GH and IGF-I in normal mammary development by examining the effects of IGF-I on formation of parameters of the MDU, and relate the findings to experimental human breast cancer development and treatment. These parameters will be examined in Ames dwarf animals (oophorectomized to remove endogenous Pg and E2), hypophysectomized, oophorectomized sexually immature mice, and nude mice. Animals will be treated with various combinations of hormones or inhibitors of IGF-I, MMP-9 or VEGF action, with and without E2 antagonists. Markers of IGF-I action (angiogenesis, MMP and VEGF production and involvement of IGFBP-3) will be evaluated by immunohistochemistry, in situ hybridization, electron microscopy and molecular biological and anatomical techniques. The potential role of IGF-I as a permissive factor for the action of PRL will also be determined.
Funding Period: 1996-08-01 - 2007-12-31
more information: NIH RePORT

Top Publications

  1. ncbi Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action
    Weifeng Ruan
    Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA
    Endocrinology 146:1170-8. 2005
  2. ncbi SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Weifeng Ruan
    Neuroendocrine Unit, New York University School of Medicine, New York, New York 10016, USA
    Mol Endocrinol 20:426-36. 2006
  3. pmc GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90
    John D Carmichael
    Neuroendocrine Unit, Division of Endocrinology, General Clinical Research Center, New York University School of Medicine, New York, NY, USA
    Clin Endocrinol (Oxf) 65:169-77. 2006
  4. ncbi Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice
    David L Kleinberg
    The Bunnie Joan Sachs Laboratory, Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Endocrinology 148:1080-8. 2007

Scientific Experts

  • D L Kleinberg
  • Weifeng Ruan
  • John D Carmichael
  • Marie E Monaco
  • Antonio P Silva
  • Elayne Livote
  • Paul D Walden
  • David R Clemmons
  • Martin L Lesser
  • Fabian Fahlbusch
  • Richard E Reitz
  • Ronenn Roubenoff
  • Steven Ferris
  • Daniela Milani
  • Herbert A Schmid
  • Ann Danoff

Detail Information

Publications4

  1. ncbi Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action
    Weifeng Ruan
    Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA
    Endocrinology 146:1170-8. 2005
    ....
  2. ncbi SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Weifeng Ruan
    Neuroendocrine Unit, New York University School of Medicine, New York, New York 10016, USA
    Mol Endocrinol 20:426-36. 2006
    ....
  3. pmc GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90
    John D Carmichael
    Neuroendocrine Unit, Division of Endocrinology, General Clinical Research Center, New York University School of Medicine, New York, NY, USA
    Clin Endocrinol (Oxf) 65:169-77. 2006
    ..To assess the GH response to GHRH-arginine in apparently healthy adults in relation to cardiovascular risk factors...
  4. ncbi Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice
    David L Kleinberg
    The Bunnie Joan Sachs Laboratory, Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Endocrinology 148:1080-8. 2007
    ..The work also provides a rationale for considering IGF-I inhibition as therapy for BPH to reduce the size of both prostate compartments...